Taiwan Liposome Company Ltd

Taiwan Liposome — Investor Presentation (February 2019)

44 slides from Taiwan Liposome's investor presentation, Feb 1, 2019

  1. Slide 1: Corporate Presentation January 2019

    Corporate Presentation January 2019

  2. Slide 2: Legal disclaimers

    Legal disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potenti

  3. Slide 3: TLC's mission presents a compelling investment opportunity

    TLC’s mission to fulfill unmet medical needs presents a compelling investment opportunity Dual-listed (Nasdaq: TLC & TWO: 4152) Dedicated management team with significant experience in liposomal science Proprietary lipid technology platforms conceiving four lead product candidates in pain management

  4. Slide 4: Experienced and dedicated management team with extensive drug development know-how

    Experienced and dedicated management team with extensive drug development know-how Name and Title Experience Prior Experience Keelung Hong, PhD >20 years research at UCSF Cancer Research Institute, biopharm consultant Founder, Chairman, CEO Co-inventor, NanoX George Yeh, MBA Joined TLC in 2002 CFO,

  5. Slide 5: Lipid-based drug delivery platforms designed to create innovative products

    Lipid-based drug delivery platforms designed to create innovative products Sustained Release 1995 Sequus/Alza/J&J Doxil Targeted Delivery 2011 Pacira Exparel 2015 Hermes/Merrimack/Ipsen Onivyde 2015 FDA Liposome Guidance ï,§ Controlled density of multi-layers for TLC599 immediate & sustained release

  6. Slide 6: A robust pipeline with pivotal stage trials planned in the next two years

    A robust pipeline with pivotal stage trials planned in the next two years Anticipated Program Preclinical Phase I Phase II Phase III Milestones Pain Management Pivotal trial TLC599 Osteoarthritis pain initiation 1H19 Ph I/II topline TLC590 Post-op pain data 1Q19 Ophthalmology TLC399 Macular edema1 P

  7. Slide 7: Osteoarthritis (OA) Pain Program TLC599

    Osteoarthritis (OA) Pain Program TLC599: BioSeizer sustained release dexamethasone sodium phosphate (DSP) intraarticular injection for OA pain

  8. Slide 8: TLC599 target product profile

    TLC599 target product profile Fast acting, long lasting, low toxicity non-opioid intraarticular injection for OA Current treatment landscape for OA ï,§ Estimated 30.8 million OA patients in US1 ï,§ Estimated 20% of people >65 years will be at risk for OA by 20302 ï,§ knee Treatment OA include for mo

  9. Slide 9: In vitro study of human chondrocytes

    In vitro study of human chondrocytes TLC599’s API dexamethasone caused the least cell death among steroids Dexamethasone, the API of TLC599, is 5 times more potent than TA, with cell death comparable to negative control (Dexamethasone) (TA, triamcinolone acetonide) Source: Dragoo et al. Knee Surg Sp

  10. Slide 10: Preclinical in vivo study – chondrotoxicity

    Preclinical in vivo study – chondrotoxicity TLC599 is cartilage sparing compared to ER TA Proteoglycan Staining Study in Beagles Day 30 Darker color = more staining = more proteoglycan presence = less cartilage damage TA = triamcinolone acetonide / ER TA = extended release triamcinolone acetonide 10

  11. Slide 11: Preclinical in vivo PK study

    Preclinical in vivo PK study TLC599 demonstrated sustained drug levels in dog joints for 120 days (pg/mL) 1000000 conc. 100000 DSP 10000 fluid 1000 Synovial 100 LLOQ=2750ng/mL 10 0 20 40 60 80 100 120 Time post-dose (days) TLC599 was intraarticularly injected into dog knee joints (n=4 dogs). Synovia

  12. Slide 12: TLC599 Phase I/II clinical trial

    TLC599 Phase I/II clinical trial WOMAC Pain/Function and VAS showed sustained reductions in pain through 12 weeks Phase I/II WOMAC1 Pain (0-4) Phase I/II VAS Pain2 Phase I/II WOMAC Physical Function (0-4) ï,§ Fast max onset within 1 week ï,§ Sustained reductions in pain through 12 weeks 1Western Ont

  13. Slide 13: TLC599 Phase II clinical trial design and demographics

    TLC599 Phase II clinical trial Design and demographics Placebo (saline) IA injection TLC599 12mg IA injection TLC599 18mg IA injection TLC599 12mg significantly reduced pain through week 12 (WOMAC pain. p=0.0027) No additional benefit seen with 18mg Data from 12mg presented as optimal dose TLC599 TL

  14. Slide 14: Phase II clinical trial – pain reduction through the visits

    Phase II clinical trial – pain reduction through the visits TLC599 showed statistical significance against placebo through 12, 16, 20, and 24 weeks Phase II WOMAC Pain (0-4) Through W12 Through W16 Through W20 Through W24 0.0 Baseline -0.2 Reduction -0.4 from Pain Change -0.6 Mean Greater LS -0.8 *

  15. Slide 15: Phase II clinical trial – pain reduction at every visit

    Phase II clinical trial – pain reduction at every visit TLC599 also showed statistical significance against placebo at every scheduled visit Phase II WOMAC Pain (0-4) 0.0 Placebo (n=25) -0.2 Baseline TLC599 12mg (n=26) -0.4 from Change-0.6 -0.8 Mean * * * LS * -1.0 * * * -1.2 0 4 8 12 16 20 24 Phase

  16. Slide 16: Phase II clinical trial – 30% durable responses

    Phase II clinical trial – 30% durable responses Majority of patients were clinically durable responders through 24 weeks Phase II WOMAC Pain (0-4) 60 p=0.0100 * p=0.0062 p=0.0090 p=0.0143 * * * 50 Responders 40 Durable 30 of (%) 20 Percentage 10 0 W12 W16 W20 W24 Phase II VAS Pain (0-10) 60 p=0.0057

  17. Slide 17: Phase II clinical trial – safety profile

    Phase II clinical trial – safety profile TLC599 was well tolerated, with comparable frequency of TEAEs to placebo Placebo TLC599 12mg TLC599 18mg n=25 n=26 n=24 TEAE 17 (68%) 18 (69.2%) 20 (83.3%) Treatment-related 4 (16%) 7 (26.9%) 11 (45.8%) TEAE Treatment-related 0 0 0 SAE Index knee-related 4 (1

  18. Slide 18: Phase II clinical trial key takeaways

    Phase II clinical trial Key takeaways  Immediate reductions in WOMAC and VAS Pain which were sustained • Placebo response generally similar to other trials, with no increase to baseline late in trial  TLC599 12mg was statistically significantly better than placebo for reductions in pain from D

  19. Slide 19: Market research study with 16-week pain control

    Market research study with 16-week pain control TLC599 could achieve usage in 26% of all US knee OA patients TLC599 Optimal Profile Fast pain Better relief as >3mo WOMAC quickly as sustained Pain 1wk pain relief Reduction Safer 21G- for repeat 30G dosing needle size Source: ZS Associates Market Stud

  20. Slide 20: Post-Surgical Pain Program TLC590

    Post-Surgical Pain Program TLC590: BioSeizer sustained release ropivacaine injection for post-operative pain management

  21. Slide 21: TLC590 target product profile

    TLC590 target product profile Fast acting, long lasting non-opioid postoperative local anesthetic for up to 72 hours Current local anesthetic landscape ï,§ 96 million surgical procedures were performed in the US in 20121 ï,§ Local anesthetics play a major role in the management of post-surgical pain

  22. Slide 22: Features comparison

    Features comparison Current data for TLC590 vs other postsurgical pain management drugs Generic ER TLC590 Product Attributes Local Bupivacaine (ER Ropivacaine) Anesthetics Sustained release formulation ✗ ✓ ✓ Lower Local anesthetic systemic toxicity (LAST) – cardiovascular1 ✗ ✗ ✓ Lower LAST – c

  23. Slide 23: Preclinical paw incision analgesic study

    Preclinical paw incision analgesic study TLC590 produced statistically significant reductions in pain compared to ER bupivacaine * * In TLC590 displayed… ï,§ Statistically significant reductions in pain at 0.5, 5, * and 6 hours post-injection compared to ER bupivacaine at equipotent dose ï,§ Earlier

  24. Slide 24: Preclinical nerve block study

    Preclinical nerve block study TLC590 exhibited more robust magnitude and duration of analgesia ï,§ TLC590 exhibited larger magnitude of analgesia which persisted to the 9th hour ï,§ Analgesic action of ER bupivacaine diminished and was comparable to saline by the 8th hour 24

  25. Slide 25: Phase I/II clinical trial – inguinal hernia repair surgery

    Phase I/II clinical trial – inguinal hernia repair surgery Trial complete – topline data readout 1Q19 Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study of TLC590 compared with free ropivacaine via a single infiltrative local administration in adult subjects following

  26. Slide 26: Phase II clinical trial – bunionectomy

    Phase II clinical trial – bunionectomy Design and objectives Phase 2, randomized, double-blind, comparator- and placebo-controlled study of TLC590 compared with free ropivacaine and placebo via a single infiltrative local administration in adult subjects following bunionectomy 152mg 190mg 228mg 50mg

  27. Slide 27: Ophthalmic Disease Program TLC399

    Ophthalmic Disease Program TLC399: BioSeizer sustained release dexamethasone sodium phosphate (DSP) intravitreal injection for macular edema (ME) due to retinal vein occlusion (RVO)

  28. Slide 28: TLC399 target product profile

    TLC399 target product profile Fast acting, long lasting non-implant dexamethasone intravitreal injection Current treatment landscape for macular edema ï,§ RVO affects >16 million adults worldwide1 ï,§ Steroids still play a prominent role in the management of RVO even post the advent of anti-VEGF2 ï,

  29. Slide 29: Administration of TLC399 potentially means less risk of bleeding/infections

    Administration of TLC399 potentially means less risk of bleeding/infections TLC399 (no implant) 30G / 0.3112mm Approved steroid implant 22G / 0.7176mm ï,§ Injections using 22G needle cause bleeding in 23% of patients1 ï,§ TLC399 uses smaller 30G needle and no implants ⇒ potentially less risk of bl

  30. Slide 30: Preclinical study: dexamethasone levels maintained for >200 days

    Preclinical study Dexamethasone levels of TLC399 in the eye maintained for >200 days TLC399 Rabbit Vitreous Dex Implant Rabbit Vitreous Maintained effective to Day 200 Concentration below LoQ by Day 35 Source: Ozurdex presentation When injected into eyes of animals… ï,§ DSP was undetectable within o

  31. Slide 31: Phase I clinical trial

    Phase I clinical trial Decrease in CST up to 12 months after single injection (0.6mg DSP) Day 0 Day 90 Day 180 Day 360 CST* 386 ìm 253 ìm 264 ìm 206 ìm * Central Subfield Thickness ï,§ Improved/stabilized vision for 6 to 12 months ï,§ Improved optical coherence tomography (OCT) results for 6 to 12 m

  32. Slide 32: Phase II clinical trial updated design

    Phase II clinical trial Updated TLC399 trial design with optimized formulation Patient Population Inclusion criteria: ï,§ M/F, >18 years old ï,§ Macular edema due to CRVO or BRVO ï,§ BCVA score 20/40 to 20/400 ï,§ CST ³ 350 um Screening Day-14 to Day-1 (n=66) Randomization Treatment Visit Groups Str

  33. Slide 33: Extending BioSeizer to anti-VEGF Ab

    Extending BioSeizer to anti-VEGF Ab: in vivo evidence of much longer duration Rabbit IVT PK Profile Measured by ELISA Effective concentration 0.5ug/ml ï,§ Concentration of Anti-VEGF can be significantly maintained from 1-2 months to >4 months when engaged with TLC’s proprietary BioSeizer technology

  34. Slide 34: Soft Tissue Sarcoma Program TLC178

    Soft Tissue Sarcoma Program TLC178: NanoX tumor-concentrated delivery of vinorelbine for rhabdomyosarcoma (RMS) and potentially for soft tissue sarcomas (STS) and non-small cell lung carcinoma (NSCLC)

  35. Slide 35: TLC178 target product profile

    TLC178 target product profile Safer, less toxic, more durable anticancer drug with RPD and ODD designations Current treatment landscape in cancers ï,§ Vinorelbine Guidelines as (VNB) therapy is listed agent by with the activity National in Comprehensive RMS in combination Cancer with Network cycloph

  36. Slide 36: Rhabdomyosarcoma (RMS) background

    Rhabdomyosarcoma (RMS) background RMS: rare, aggressive, most common soft tissue cancer in kids with about 350 cases per year Incidence Annually 350 new cases in the US1 Cure rate 70% for multimodality treatment2 Vincristine, vinorelbine (although not approved by FDA for Common practice use in RMS)

  37. Slide 37: Preclinical study – fibrosarcoma model

    Preclinical study – fibrosarcoma model TLC178 showed significant tumor inhibition response compared to doxorubicin (p<0.05) Antitumor Efficacy of TLC178 in Fibrosarcoma Model 2000 Placebo (D5W) Doxorubicin 3.4mg/kg TLC178 5mg/kg 1500 3 ) (mm volume 1000 Tumor 500 0 0 5 10 15 20 25 30 Post drug injec

  38. Slide 38: Preclinical study – RMS model

    Preclinical study – RMS model TLC178 demonstrated more effective control of tumor growth than free vinorelbine Antitumor Efficacy of TLC178 in RMS Model Saline 3000 Vinorelbine 5mg/kg TLC178 5mg/kg TLC178 superior to vinorelbine (p<0.05) from day 18 onwards 2500 3 ) Compared to free vinorelbine, (mm

  39. Slide 39: Preclinical study – NSCLC model

    Preclinical study – NSCLC model TLC178 demonstrated superior control of tumor growth over VNB and VNB + Gem Antitumor Efficacy of TLC178 alone and with Gem in NSCLC Model 2500 Saline 5mg/kg VNB 5mg/kg TLC178 5mg/kg VNB + 25mg/kg Gem 2000 5mg/kg TLC178 + 25mg/kg Gem 3 )ï,§ TLC178 showed better (mm 15

  40. Slide 40: Clinical development plan for TLC178

    Clinical development plan for TLC178 in pRMS with extended indications in STS and NSCLC 3+3 Dose Escalation Mono TLC178 MTD (n=30-50) Current trial status: ,§ N=23 (current dose: 34mg/m2) ï,§ 1 treatment-related hematological toxicity (neutropenia) which was not a DLT Pediatric Rhabdomyosarcoma (pRM

  41. Slide 41: TLC Summary

    TLC Summary

  42. Slide 42: Anticipated short- and long-term milestones

    Anticipated short- and long-term milestones All programs expected to be in late or pivotal stage within two years Phase TLC599 II PK topline data TLC599 EOP2 meeting (CMC) TLC590 (bunionectomy) Phase II topline data TLC599 Fast track designation TLC399 Pivotal TLC599 trial topline data submission Ph

  43. Slide 43: TLC—Key takeaways

    TLC—Key takeaways  Experienced management team ï,§ CEO Dr. Keelung Hong’s third liposome company; President George Yeh’s second ï,§ Over 150 years of experience on management team  Robust and diverse pipeline ï,§ Programs targeting areas of unmet need in pain management (TLC599 & TLC590), opht

  44. Slide 44: Thank You

    Thank YouDelivering Hope for life

Taiwan Liposome Company — Investor Presentation (February 2019) on 6ix